These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 29477396)

  • 21. Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report.
    Mauskopf J; Standaert B; Connolly MP; Culyer AJ; Garrison LP; Hutubessy R; Jit M; Pitman R; Revill P; Severens JL
    Value Health; 2018 Oct; 21(10):1133-1149. PubMed ID: 30314613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-utility analysis: use QALYs only with great caution.
    McGregor M
    CMAJ; 2003 Feb; 168(4):433-4. PubMed ID: 12591784
    [No Abstract]   [Full Text] [Related]  

  • 23. Healthcare expert panel: health cost drivers and consumer empowerment.
    Goodman BJ; O'Kane M; Owens G
    Dis Manag; 2004; 7 Suppl 2():S9-14. PubMed ID: 15801370
    [No Abstract]   [Full Text] [Related]  

  • 24. Legislating against use of cost-effectiveness information.
    Neumann PJ; Weinstein MC
    N Engl J Med; 2010 Oct; 363(16):1495-7. PubMed ID: 20942664
    [No Abstract]   [Full Text] [Related]  

  • 25. Review: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Goettsch WG; Enzing J
    Value Health; 2014; 17(1):1-2. PubMed ID: 24438710
    [No Abstract]   [Full Text] [Related]  

  • 26. Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report.
    Brazier J; Ara R; Azzabi I; Busschbach J; Chevrou-Séverac H; Crawford B; Cruz L; Karnon J; Lloyd A; Paisley S; Pickard AS
    Value Health; 2019 Mar; 22(3):267-275. PubMed ID: 30832964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ISPOR states its position on network meta-analysis.
    Ades AE
    Value Health; 2011 Jun; 14(4):414-6. PubMed ID: 21669365
    [No Abstract]   [Full Text] [Related]  

  • 28. Health economics. A bridge over troubled water.
    Brouwer WB; Rutten FF
    Eur J Public Health; 2001 Jun; 11(2):234-6. PubMed ID: 11420818
    [No Abstract]   [Full Text] [Related]  

  • 29. ISPOR Code of Ethics for Researchers background article--report of the ISPOR Task Force on Code of Ethics for Researchers.
    Palumbo FB; Barnes R; Deverka P; McGhan W; Mullany L; Wertheimer A;
    Value Health; 2004; 7(2):111-7. PubMed ID: 15164801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A quest for certainty: views, memoirs, and predictions on health care economics.
    Rorem CR
    Inquiry; 1982; 19(2):99-104. PubMed ID: 6212547
    [No Abstract]   [Full Text] [Related]  

  • 31. The economics of health care.
    Rineberg BA
    Orthopedics; 1991 Mar; 14(3):377. PubMed ID: 1902293
    [No Abstract]   [Full Text] [Related]  

  • 32. Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report--Part III.
    Mansley EC; Carroll NV; Chen KS; Shah ND; Piech CT; Hay JW; Smeeding J
    Value Health; 2010; 13(1):14-7. PubMed ID: 19883404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The future of health economic modeling: have we gone too far or not far enough?
    Fendrick AM
    Value Health; 2006; 9(3):179-80. PubMed ID: 16689711
    [No Abstract]   [Full Text] [Related]  

  • 34. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV.
    Mullins CD; Seal B; Seoane-Vazquez E; Sankaranarayanan J; Asche CV; Jayadevappa R; Lee WC; Romanus DK; Wang J; Hay JW; Smeeding J
    Value Health; 2010; 13(1):18-24. PubMed ID: 19807903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Yes, Improve the US Value Frameworks, But Recognize They Are Already in Prime Time.
    Neumann PJ
    Value Health; 2019 Sep; 22(9):975-976. PubMed ID: 31511185
    [No Abstract]   [Full Text] [Related]  

  • 36. Patient-centered medical homes in Louisiana had minimal impact on Medicaid population's use of acute care and costs.
    Cole ES; Campbell C; Diana ML; Webber L; Culbertson R
    Health Aff (Millwood); 2015 Jan; 34(1):87-94. PubMed ID: 25561648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A primer on cost-effectiveness in the allergy clinic.
    Shaker M; Greenhawt M
    Ann Allergy Asthma Immunol; 2019 Aug; 123(2):120-128.e1. PubMed ID: 31128234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force.
    Bridges JF; Hauber AB; Marshall D; Lloyd A; Prosser LA; Regier DA; Johnson FR; Mauskopf J
    Value Health; 2011 Jun; 14(4):403-13. PubMed ID: 21669364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determinants of health economic decisions in actual practice: the role of behavioral economics. Summary of the presentation given by Professor Daniel Kahneman at the ISPOR 10th Annual International Meeting First Plenary Session, May 16, 2005, Washington, DC, USA.
    Value Health; 2006; 9(2):65-7. PubMed ID: 16626409
    [No Abstract]   [Full Text] [Related]  

  • 40. Controlling U.S. health care spending--separating promising from unpromising approaches.
    Hussey PS; Eibner C; Ridgely MS; McGlynn EA
    N Engl J Med; 2009 Nov; 361(22):2109-11. PubMed ID: 19907037
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.